title: Adenosine 2A receptor agonism: A single intrathecal administration attenuates motor paralysis in experimental autoimmune encephalopathy in rats.
abstract: A single intrathecal dose of adenosine 2A receptor (A2AR) agonist was previously reported to produce a multi-week reversal of allodynia in two different models of neuropathic pain in addition to downregulating glial activation markers in the spinal cord. We aimed to determine whether a single intrathecal administration of an A2AR agonist was able to attenuate motor symptoms induced by experimental autoimmune encephalopathy. Two A2AR agonists (CGS21680 and ATL313) significantly attenuated progression of motor symptoms following a single intrathecal administration at the onset of motor symptoms. OX-42, a marker of microglial activation, was significantly attenuated in the lumbar spinal cord following A2AR administration compared to vehicle. Therefore, A2AR agonists attenuate motor symptoms of EAE by acting on A2AR in the spinal cord.
authors: Dept. Psychology & Neuroscience, Center for Neuroscience, Univ. Colorado-Boulder, Boulder, CO, USA. Electronic address: Lisa.Loram@me.com.
authors: Lisa C
authors: LC
authors: Loram
authors: Dept. Psychology & Neuroscience, Center for Neuroscience, Univ. Colorado-Boulder, Boulder, CO, USA.
authors: Keith A
authors: KA
authors: Strand
authors: Dept. Psychology & Neuroscience, Center for Neuroscience, Univ. Colorado-Boulder, Boulder, CO, USA.
authors: Frederick R
authors: FR
authors: Taylor
authors: Dept. Psychology & Neuroscience, Center for Neuroscience, Univ. Colorado-Boulder, Boulder, CO, USA.
authors: Evan
authors: E
authors: Sloane
authors: Department of Anatomy and Neurosciences, VU University Medical Center, Amsterdam, The Netherlands.
authors: Anne-Marie
authors: AM
authors: Van Dam
authors: Dogwood Pharmaceuticals, Inc., Forest Labs, Inc., Charlottesville, VA, USA.
authors: Jayson
authors: J
authors: Rieger
authors: Dept. Psychology & Neuroscience, Center for Neuroscience, Univ. Colorado-Boulder, Boulder, CO, USA.
authors: Steven F
authors: SF
authors: Maier
authors: Dept. Psychology & Neuroscience, Center for Neuroscience, Univ. Colorado-Boulder, Boulder, CO, USA.
authors: Linda R
authors: LR
authors: Watkins
mesh_terms: D000241:Adenosine / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D058908:Adenosine A2 Receptor Agonists / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000188:drug therapy*; D008297:Male; D017628:Microglia / Q000187:drug effects; D010243:Paralysis / Q000188:drug therapy*; D010627:Phenethylamines / Q000494:pharmacology / Q000627:therapeutic use; D010880:Piperidines / Q000494:pharmacology / Q000627:therapeutic use; D051381:Rats; D013116:Spinal Cord / Q000187:drug effects*
chemical_list: C510376:ATL 313; D058908:Adenosine A2 Receptor Agonists; D010627:Phenethylamines; D010880:Piperidines; C061282:2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine; D000241:Adenosine
keywords: ATL313; CGS21680; Multiple sclerosis; Myelin oligodendrocyte glycoprotein
references: Inflammation. 2013 Aug;36(4):921-31
references: 23504259
references: Nat Rev Immunol. 2008 Dec;8(12):958-69
references: 19029990
references: Brain Behav Immun. 2013 Oct;33:112-22
references: 23811314
references: Inflamm Allergy Drug Targets. 2013 Dec;12(6):391-402
references: 24090317
references: Neuropharmacology. 2014 Nov;86:203-11
references: 25019206
references: BMC Infect Dis. 2008;8:141
references: 18937852
references: Brain Behav Immun. 2009 Jan;23(1):92-100
references: 18835435
references: J Neurosci. 2009 Nov 4;29(44):14015-25
references: 19890011
references: Brain Res. 2010 Jan 14;1309:116-25
references: 19879252
references: Rev Neurosci. 2011;22(2):231-9
references: 21476942
references: Nat Neurosci. 2011 Sep;14(9):1142-9
references: 21804537
references: J Immunol. 2012 Jun 1;188(11):5713-22
references: 22529293
references: J Neurochem. 2012 Oct;123(1):100-12
references: 22639925
references: J Immunol. 2013 Jan 1;190(1):138-46
references: 23225885
references: Ann Neurol. 2001 May;49(5):650-8
references: 11357956
references: J Neuroimmunol. 2003 Mar;136(1-2):94-103
references: 12620647
references: Trends Immunol. 2004 Jan;25(1):33-9
references: 14698282
references: J Neurosci. 2004 Feb 11;24(6):1521-9
references: 14960625
references: Pharmacol Ther. 2007 Feb;113(2):264-75
references: 17056121
references: J Exp Med. 2007 Jun 11;204(6):1257-65
references: 17502665
references: Physiol Behav. 2007 Sep 10;92(1-2):15-20
references: 17574632
references: Blood. 2008 Jan 1;111(1):251-9
references: 17909080
references: Proc Natl Acad Sci U S A. 2008 Jul 8;105(27):9325-30
references: 18591671
references: Blood. 2013 Sep 12;122(11):1935-45
references: 23908469